Risks and Benefits of Hormonal Manipulation as Monotherapy or Adjuvant Treatment in Localised Prostate Cancer

This publication has 20 references indexed in Scilit:

• 303Patients with asymptomatic prostate cancer T.0-4 N.0-2 M.0 not suitable for local definitive treatment: Do they need immediate androgen deprivation?
  European Urology Supplements, 2005
• BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARS
  Journal of Urology, 2004
• Immediate Versus Deferred Hormonal Treatment for Patients With Prostate Cancer Who Are Not Suitable for Curative Local Treatment: Results of the Randomized Trial SAKK 08/88
  Journal of Clinical Oncology, 2004
• Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy
  Journal of Urology, 2004
• 217 Increase in the electrocardiographic QTC interval in men with prostate cancer undergoing androgen deprivation therapy: Results of three randomized controlled clinical studies
  European Urology Supplements, 2004
• Altered cognitive function in men treated for prostate cancer with luteinizing hormone‐releasing hormone analogues and cyproterone acetate: a randomized controlled trial
  BJU International, 2002
• SKELETAL FRACTURE ASSOCIATED WITH ANDROGEN SUPPRESSION INDUCED OSTEOPOROSIS: THE CLINICAL INCIDENCE AND RISK FACTORS FOR PATIENTS WITH PROSTATE CANCER
  Journal of Urology, 2001
• Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study
  Journal of Clinical Oncology, 2001
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial
  British Journal of Urology, 1997
• The veterans administration cooperative urological research group's studies of cancer of the prostate
  Cancer, 1973